Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharm...( Renowned oncologists bring decad...),Health
Renowned oncologists bring decades of cancer research and clinical
development experience to Celator.
PRINCETON, N.J., Nov. 28 /PRNewswire/ -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced two recent appointments to its Scientific Advisory Board: Frederick R. Appelbaum, M.D., head of the University of Washington School of Medicine's Division of Medical Oncology and President of the Seattle Cancer Care Alliance (SCCA); and Ross C. Donehower, M.D., Professor of Oncology and Medicine at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Dr. Appelbaum is the author of more than 800 articles and is active on the editorial boards of many scientific journals. He is a current or former member of a number of national scientific committees including the Board of Scientific Advisors of the National Cancer Institute. Dr. Appelbaum is a graduate of Dartmouth College and of Tufts University School of Medicine. Prior to joining the faculty of the University of Washington in 1978, Dr. Appelbaum was a clinical associate and investigator with the National Cancer Institute in Bethesda, MD.
Dr. Donehower is also Director of the Division of Medical Oncology at The Johns Hopkins Oncology Center. His clinical research has focused on the treatment of gastrointestinal and lung cancers as well as new drug development. He has authored over 150 scientific publications and sits on the editorial board of numerous prestigious scientific journals. Before joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate with the National Cancer Institute. Dr. Donehower received his medical training at the University of Minnesota.
"We are delighted to welcome Dr. Appelbaum and Dr. Donehower to
Celator's Scientific Advisory Board," said Andrew Janoff, Ph.D
'/>"/>
| SOURCE Celator Pharmaceuticals Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Frederick J. Ferrer Named New CEO of The Health Trust
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. Thomson Scientific Predicts Nobel Laureates
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Thomson Scientific Announces BONDplus for Biological Researchers
6. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
7. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
10. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
11. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |